FINWIRES · TerminalLIVE
FINWIRES

ImmuneOnco to Trim Stake in ImmuneCare via Jiaxing Changxin Deal

By

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) will lower its stake in ImmuneCare Biopharmaceutical (Shanghai) under a capital increase agreement with the latter's employee shareholding platform.

Specifically, Jiaxing Changxin will subscribe for shares worth 325,000 yuan of the metabolic and rare disease-focused drug development company, according to a filing late Thursday.

Upon deal completion, the Hong Kong-listed clinical-stage biotechnology company will own 80% of ImmuneCare, down from 93.0% due to dilution, while Jiaxing Changxin will hold the remaining 20%.

Related Articles

Asia

Singapore Welcomes US-Iran Peace Deal, Commends Mediators

Singapore has welcomed the signing of a memorandum of understanding between the U.S. and Iran to end hostilities and establish a framework for further negotiations, according to an official statement by the Ministry of Foreign Affairs on Thursday.The ministry commended the mediatory role played by Pakistan and Qatar to broker an interim deal between the two sides, while also welcoming the commitment to reopen the Strait of Hormuz.U.S. President Donald Trump signed the deal in France during the G7 summit, while the president of Iran, Masoud Pezeshkian, signed the document on Wednesday.

^STI
Asia

Keppel Repurchases Shares Worth SG$2.3 Million

Keppel (SGX:BN4) bought back 200,000 shares in the open market on Wednesday for nearly SG$2.3 million, according to a same-day filing with the Singapore Exchange.The infrastructure and real estate company has so far repurchased over 11 million shares under its existing buyback mandate.

SGX:BN4
Asia

Teco Electric and Machinery Unit Leases Office Space for NT$22 Million

Teco Electric and Machinery (TPE:1504) TECNOS International Consulting acquired the right to use office space in Taipei, Taiwan, for NT$22.4 million, according to a Thursday Taiwan Exchange filing.Shares gained about 2% in Friday's late morning trade.The assets will be purchased from related party Tong-An Assets Development & Management.The lease term runs from July 1, 2026, to June 30, 2032, and the office space will be used to meet operational requirements.

TPE:1504
ImmuneOnco to Trim Stake in ImmuneCare via Jiaxing Changxin Deal | FINWIRES